AtriCure (ATRC) Projected to Post Earnings on Tuesday

AtriCure (NASDAQ:ATRC - Get Free Report) is expected to be announcing its Q2 2025 earnings results after the market closes on Tuesday, July 29th. Analysts expect the company to announce earnings of ($0.15) per share and revenue of $130.17 million for the quarter. AtriCure has set its FY 2025 guidance at -0.550--0.500 EPS.

AtriCure (NASDAQ:ATRC - Get Free Report) last issued its quarterly earnings data on Tuesday, April 29th. The medical device company reported ($0.14) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.25) by $0.11. AtriCure had a negative return on equity of 5.68% and a negative net margin of 7.95%. The business had revenue of $123.62 million during the quarter, compared to analyst estimates of $122.92 million. During the same period in the prior year, the company posted ($0.28) EPS. The business's revenue for the quarter was up 13.5% compared to the same quarter last year. On average, analysts expect AtriCure to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

AtriCure Stock Performance

ATRC stock traded up $0.59 on Friday, reaching $30.76. The company's stock had a trading volume of 99,645 shares, compared to its average volume of 562,128. AtriCure has a 52 week low of $20.20 and a 52 week high of $43.11. The company has a market capitalization of $1.52 billion, a P/E ratio of -37.86 and a beta of 1.56. The firm has a fifty day moving average of $32.30 and a two-hundred day moving average of $34.31. The company has a debt-to-equity ratio of 0.16, a current ratio of 4.11 and a quick ratio of 2.88.

Insider Buying and Selling at AtriCure

In other news, insider Vinayak Doraiswamy sold 2,500 shares of the company's stock in a transaction on Wednesday, May 28th. The shares were sold at an average price of $33.44, for a total value of $83,600.00. Following the transaction, the insider directly owned 73,550 shares of the company's stock, valued at approximately $2,459,512. This represents a 3.29% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Company insiders own 3.50% of the company's stock.

Hedge Funds Weigh In On AtriCure

Hedge funds have recently modified their holdings of the stock. Goldman Sachs Group Inc. increased its stake in shares of AtriCure by 1.0% in the first quarter. Goldman Sachs Group Inc. now owns 862,668 shares of the medical device company's stock worth $27,830,000 after acquiring an additional 8,956 shares during the last quarter. Jane Street Group LLC increased its stake in shares of AtriCure by 658.3% in the first quarter. Jane Street Group LLC now owns 100,853 shares of the medical device company's stock worth $3,254,000 after acquiring an additional 87,553 shares during the last quarter. AQR Capital Management LLC increased its stake in shares of AtriCure by 1.0% in the first quarter. AQR Capital Management LLC now owns 83,685 shares of the medical device company's stock worth $2,700,000 after acquiring an additional 837 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in shares of AtriCure by 4.6% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 28,146 shares of the medical device company's stock worth $908,000 after acquiring an additional 1,230 shares during the last quarter. Finally, Strs Ohio acquired a new position in shares of AtriCure in the first quarter worth $158,000. 99.11% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

ATRC has been the subject of a number of research reports. JPMorgan Chase & Co. decreased their price target on AtriCure from $51.00 to $46.00 and set an "overweight" rating for the company in a research note on Thursday, March 27th. Wall Street Zen lowered AtriCure from a "buy" rating to a "hold" rating in a research note on Sunday, June 1st. BTIG Research reaffirmed a "buy" rating on shares of AtriCure in a research note on Thursday, March 27th. Needham & Company LLC cut their price objective on AtriCure from $51.00 to $44.00 and set a "buy" rating for the company in a research report on Wednesday, April 30th. Finally, Canaccord Genuity Group cut their price objective on AtriCure from $66.00 to $52.00 and set a "buy" rating for the company in a research report on Friday, March 28th. One equities research analyst has rated the stock with a hold rating and nine have issued a buy rating to the company. According to MarketBeat, AtriCure currently has a consensus rating of "Moderate Buy" and a consensus target price of $50.67.

AtriCure Company Profile

AtriCure, Inc develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation.